BIOA · BioAge Labs Inc
United States · RS rating 14 · As of 2026-11-03
| Price | 5.96 USD |
|---|---|
| 1-day change | +2.8% |
| RS rating (overall / 1M / 3M / 12M) | 14 / 42 / 11 / 36 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 4 / 17 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | -11.5% |
| Sales growth Q/Q | +49.9% |
| Distance from 52-week high | +76.2% |
| Market cap (USD) | $765.4M |